Neurocardiogenic syncope: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
(8 intermediate revisions by 4 users not shown)
Line 1: Line 1:
'''For patient information on this page, click [[Neurocardiogenic syncope (patient information)|here]]'''


{{Neurocardiogenic syncope}}
{{CMG}}


==ACC / AHA Guidelines- Permanent Pacing in Hypersensitive Carotid Sinus Syndrome and Neurocardiogenic Syncope (DO NOT EDIT) <ref name="Epstein"> Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008; 117: 2820–2840. PMID 18483207 </ref>==
==[[Neurocardiogenic syncope overview|Overview]]==
{{cquote| 
===Class I===
1. Permanent [[pacemaker|pacing]] is indicated for recurrent [[syncope]] caused by spontaneously occurring [[carotid sinus]] stimulation and [[carotid sinus]] pressure that induces [[ventricular asystole]] of more than 3 seconds. ''(Level of Evidence: C)''


===Class IIa===
==[[Neurocardiogenic syncope pathophysiology|Pathophysiology]]==
1. Permanent [[pacemaker|pacing]] is reasonable for [[syncope]] without clear, provocative events and with a hypersensitive cardioinhibitory response of 3 seconds or longer. ''(Level of Evidence: C)''


===Class IIb===
==[[Neurocardiogenic syncope epidemiology and demographics|Epidemiology & Demographics]]==
1. Permanent [[pacemaker|pacing]] may be considered for significantly symptomatic neurocardiogenic [[syncope]] associated with [[bradycardia]] documented spontaneously or at the time of tilt-table testing. ''(Level of Evidence: B)''


===Class III===
==[[Neurocardiogenic syncope risk factors|Risk Factors]]==
1. Permanent [[pacemaker|pacing]] is not indicated for a hypersensitive cardioinhibitory response to [[carotid sinus]] stimulation without symptoms or with vague symptoms. ''(Level of Evidence: C)''


2. Permanent [[pacemaker|pacing]] is not indicated for situational vasovagal [[syncope]] in which avoidance behavior is effective and preferred. ''(Level of Evidence: C)''}}
==[[Neurocardiogenic syncope causes|Causes]]==


==Sources==
==[[Neurocardiogenic syncope natural history|Natural History, Prognosis & Complication]]==
* The ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities <ref name="Epstein"> Epstein AE, DiMarco JP, Ellenbogen KA, Estes NAM III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Circulation. 2008; 117: 2820–2840. PMID 18483207 </ref>


==References==
==[[Neurocardiogenic syncope differentiating from other diseases|Differentiating Neurocardiogenic Syncope From Other Diseases]]==
{{reflist|2}}
# Neurocardiogenic syncope. Carol Chen-Scarabelli, Tiziano M Scarabelli. BMJ 2004;329:336–41
# Brignole M, Alboni P, Benditt D, Bergfeldt L, Blanc JJ, Bloch Thomsen PE, et al for the Task Force on Syncope, European Society of Cardiology.Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256-306.
# Vasovagal Syncope. Alexis M. Fenton, MD; Stephen C. Hammill, MD; Robert F. Rea, MD; Phillip A. Low, MD; and Win-Kuang Shen, MD. Ann Intern Med. 2000;133:714-725.
# Connolly SJ, Sheldon R, Thorpe KE, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289:2224-9.


{{SIB}}
==Diagnosis==
[[Neurocardiogenic syncope symptoms|History & Symptoms]] | [[Neurocardiogenic syncope physical examination|Physical Examination]] | [[Neurocardiogenic syncope electrocardiogram|Electrocardiogram]] | [[Neurocardiogenic syncope chest x-ray|Chest X-Ray]] | [[Neurocardiogenic syncope tilt table testing|Tilt table test]] | [[Neurocardiogenic syncope echocardiography|Echocardiography]] | [[Neurocardiogenic syncope cardiac catheterization|Cardiac Catheterization]]


==Treatment==
====[[Neurocardiogenic syncope medical treatment|Medical Therapy]]====
====[[Neurocardiogenic syncope pacemaker therapy|Pacemaker Therapy]]====
==Related Chapters==
*[[Vasovagal syncope]]
*[[Postural orthostatic tachycardia syndrome]]
*[[Dysautonomia]]
[[Category:Disease]]
[[Category:Cardiology]]
[[Category:Cardiology]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 17:51, 20 July 2012

For patient information on this page, click here

Neurocardiogenic Syncope Microchapters

Home

Patient Info

Overview

Pathophysiology

Epidemiology and Demographics

Risk Factors

Causes

Natural History, Complications & Prognosis

Differentiating Neurocardiogenic Syncope From Other Diseases

Diagnosis

History & Symptoms

Physical Examination

Tilt Table Testing

Treatment

Pharmacotherapy

Pacemaker therapy

Neurocardiogenic syncope On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurocardiogenic syncope

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurocardiogenic syncope

CDC on Neurocardiogenic syncope

Neurocardiogenic syncope in the news

Blogs on Neurocardiogenic syncope

Directions to Hospitals Treating Neurocardiogenic Syncope

Risk calculators and risk factors for Neurocardiogenic syncope

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Epidemiology & Demographics

Risk Factors

Causes

Natural History, Prognosis & Complication

Differentiating Neurocardiogenic Syncope From Other Diseases

Diagnosis

History & Symptoms | Physical Examination | Electrocardiogram | Chest X-Ray | Tilt table test | Echocardiography | Cardiac Catheterization

Treatment

Medical Therapy

Pacemaker Therapy

Related Chapters


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Neurocardiogenic_syncope&oldid=655262"